Integrity CE, LLC’s Post

Incredible, game-changing results that have the potential to alter the treatment landscape in first-line NSCLC by challenging Keytruda’s dominance in this space; however, there are some important considerations: *First and foremost, the data is from a smaller population and one country - it will be interesting to see if the clinical benefit is translated in patients outside China in larger population *PFS data at a longer follow-up time point would provide clarity on how the reduction in the risk of progression or death translates to statistically significant survival benefit *OS data would be needed to secure the regulatory approval - this would be against a competitor that has shown OS improvement in several NSCLC patient populations *Safety results will consolidate its position as a better alternative Finally, outside this population: *How it performs in nonsquamous NSCLC patients, is yet to be seen *Also, it will be interesting to see how it performs in PD-L1 high frontline patients That said, it’s a great news for the patients and a big win for science!

Striking Results! 🫁 Discovered by the China-based biotech, Akeso, #ivonescimab works differently than Keytruda, which blocks the immune-regulating protein PD-1. Rather, it simultaneously stifles PD-1 and another target implicated in tumor growth, called VEGF. While there are other cancer medicines that inhibit VEGF, obstructing both pathways with a single therapy might have enhanced benefit. 💥 Ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with PD-L1-positive advanced non-small cell lung cancer! Professor Caicun Zhou, MD, PhD, Chief Physician and Director of the Department of Medical Oncology at Shanghai Pulmonary Hospital, Tongji University School of Medicine, and President-Elect of IASLC, reported the groundbreaking data of HARMONi-2 at the Presidential Symposium of the #WCLC2024. 💥 Ivonescimab demonstrated a clinically meaningful mPFS of 11.14 months vs. 5.82 months with pembrolizumab. 💥 Ivonescimab significantly reduced the risk of disease progression or death by 49% vs. pembrolizumab, with a PFS HR of 0.51 (P<0.0001). 💥 Ivonescimab significantly improved the ORR to 50.0% vs. 38.5% with pembrolizumab, and the DCR was 89.9% vs.70.5%. 💥 PD-L1 high and low expression subgroups: In the PD-L1 TPS ≥50% population, ivonescimab achieved a PFS HR of 0.46 vs. pembrolizumab. In the PD-L1 TPS 1-49% population, the PFS HR was 0.54. 💥 Squamous and non-squamous histologies subgroups: In squamous NSCLC, ivonescimab showed a PFS HR of 0.48; in non-squamous NSCLC, the PFS HR was 0.54. 💥 Refractory subgroups: Ivonescimab showed significantly better clinical benefits compared to pembrolizumab in refractory patient populations, including those with liver metastases and brain metastases. 🌟 WOW! Possible practice-changing results in #NSCLC! What an honor to live during these times where our research in lung cancer has come so far, and to see patients benefiting from that research in real time, in our families, in our friendships, and for so many whom we love enduring the struggle of beating cancer.

Key opinion leaders outline a case study of a patient with metastatic castration-sensitive #ProstateCancer, detailing the chosen treatment approaches and the overall outcome of the case. #pcsm #oncology https://lnkd.in/eckMriPt

#ClinicalTrials #Oncology #LabConnect Clinical Trials in Oncology East Coast kicks off today! Comment below if you’re attending. ⬇️ Meet up with Sean Hansel and Scott Keddy, MBA at booth #25 to discover how LabConnect’s tailor-made solutions can expedite your targeted therapy.

Check out this free, case-based #breastcancer #CME: https://bit.ly/4fQmkHD Learn about optimal treatment selection from the available CDK 4/6i combinations and clinical trials, including MONARCH-3, PALOMA-2, and️ MONALEESA-2. #MedEd #FOAMed #Oncology

Read the blog: https://ow.ly/YCiM50S31if EVERSANA's Value & Evidence team synthesized the effectiveness of treatments received in the real-world setting after 1L CDK4/6i therapy in patients with HR+/HER2- LABC/mBC. This comprehensive systematic literature review aimed to shed light on the real-world effectiveness of treatments administered after 1L CDK4/6.. Explore their findings and understand the complexities of post-CDK4/6i therapies. #BreastCancer #Oncology Sarah Kane, Belal Howidi, Bao-Ngoc Nguyen, Joanna Bielecki and Imtiaz A. Samjoo

The journey of a breast cancer patient is challenging enough without the added burden of CIPN, chemotherapy-induced peripheral neuropathy, a devastating side effect of taxane-based chemotherapies. Listen in as our CEO, Bob Linke, explains how Osmol's OSM-0205 aims to prevent nerve damage, allowing patients to continue their life-saving treatments without compromising their quality of life. Learn more at our lead candidate as we prepare to initiate clinical development later this year for OSM-0205: https://bit.ly/4c4jFHj #biopharma #oncology #clinicaltrials

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China Full Press Release Here: https://lnkd.in/gAvUNM_N #SummitTherapeutics #oncology #WCLC24 #IASLC #Ivonescimab

Comparative Outcomes and Failure Rates of Total Femur Replacement in Oncologic and Nononcologic Indications #oncology https://bit.ly/4bDU73d

What are the early safety and activity profiles of a first-in-class PD-1/IL-2 bispecific in patients with solid tumors? 👉 Connect today to the #ESMOVirtualPlenary with international experts in #oncology to stay up to date with the latest in #immunotherapy 🔗 https://ow.ly/1nXn50SgEi0